DrugPatentWatch Archives
Click here to return to the current data set
|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Generic Name: tacrolimus
Summary for Generic Name: tacrolimus
| |||||||||||||||
Clinical Trials for: tacrolimusEfficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients Status: Completed Condition: Liver Transplantation Pharmacokinetics of Tacrolimus in Liver Transplantation Patients Treated With Prograf and Modified Release Tacrolimus Status: Completed Condition: Liver Transplantation Mycophenylate Mofetil and Tacrolimus Versus Tacrolimus for the Treatment of Idiopathic Membranous Glomerulonephritis (IMG) Status: Recruiting Condition: Nephrotic Syndrome Secondary to Idiopathic Membranous Glomerulonephritis A Study to Assess the Pharmacokinetics, Safety and Efficacy of Advagraf and Prograf in de Novo Liver Transplantation Status: Recruiting Condition: Liver Transplantation Pharmacokinetics of Generic to Brand Tacrolimus in Stable Renal Transplant Patients Status: Completed Condition: Renal Transplant TOP-Study (Tacrolimus Organ Perfusion): Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion Status: Recruiting Condition: Terminal Liver Disease; Ischemia Reperfusion Injury; Graft Dysfunction; Graft Failure; Poor Graft Quality Non-inferiority Study of the Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Patients Status: Active, not recruiting Condition: Kidney Transplant Pharmacokinetic Drug Interaction Between Ezetimibe and Tacrolimus After Single Dose Administration in Healthy Subjects Status: Completed Condition: Pharmacokinetics; Drug Interactions; Hypercholesterolemia; Immunosuppression Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) Status: Active, not recruiting Condition: Leukemia, Myelocytic, Acute; Leukemia, Lymphocytic, Acute; Leukemia, Myeloid, Chronic; Myelodysplastic Syndromes FK506 (Tacrolimus) in Pulmonary Arterial Hypertension Status: Recruiting Condition: Pulmonary Arterial Hypertension Courtesy of ClinicalTrials.org See more clinical trials for this drug | |||||||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Patent Expiration | Patented / Exclusive Use | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astellas | PROGRAF | tacrolimus | CAPSULE; ORAL | 050708 | Apr 8, 1994 | RX | No | <disabled> | ORPHAN DRUG EXCLUSIVITY | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Astellas | PROGRAF | tacrolimus | CAPSULE; ORAL | 050708 | Apr 8, 1994 | RX | Yes | <disabled> | ORPHAN DRUG EXCLUSIVITY | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Astellas | PROGRAF | tacrolimus | CAPSULE; ORAL | 050708 | Aug 24, 1998 | RX | No | <disabled> | ORPHAN DRUG EXCLUSIVITY | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Astellas | PROGRAF | tacrolimus | INJECTABLE; INJECTION | 050709 | Apr 8, 1994 | RX | Yes | <disabled> | ORPHAN DRUG EXCLUSIVITY | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
« Back to Dashboard
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc